瑞康医药
(002589)
| 流通市值：40.42亿 | | | 总市值：44.54亿 |
| 流通股本：13.66亿 | | | 总股本：15.05亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,756,650,456.75 | 7,966,345,576.74 | 6,056,194,532.51 | 4,031,665,203.8 |
| 营业收入 | 1,756,650,456.75 | 7,966,345,576.74 | 6,056,194,532.51 | 4,031,665,203.8 |
| 二、营业总成本 | 1,764,616,859.72 | 8,019,365,853.25 | 5,997,705,441.86 | 3,997,336,554.85 |
| 营业成本 | 1,513,399,174.43 | 7,090,142,842.63 | 5,265,530,452.49 | 3,525,841,738.41 |
| 税金及附加 | 9,490,020.92 | 36,911,093.36 | 26,800,898.1 | 17,069,856.86 |
| 销售费用 | 83,688,140.77 | 360,488,816.84 | 275,357,168.85 | 190,452,112.1 |
| 管理费用 | 105,913,581.75 | 394,898,420.55 | 293,252,275.18 | 175,152,600.54 |
| 研发费用 | 2,954,283.92 | 10,029,115.45 | 7,566,022.65 | 5,479,545.12 |
| 财务费用 | 49,171,657.93 | 126,895,564.42 | 129,198,624.59 | 83,340,701.82 |
| 其中:利息费用 | 75,530,939.35 | 193,866,434.08 | 166,706,929.51 | 108,093,221.28 |
| 其中:利息收入 | 31,600,653.3 | 87,891,880.27 | 59,335,714.37 | 44,112,222.96 |
| 加:公允价值变动收益 | -890,896.12 | 30,647,078.86 | 12,464,457.63 | - |
| 加:投资收益 | 5,233,028.06 | 96,213,121.33 | 29,014,904.55 | 32,150,163.64 |
| 资产处置收益 | -92,101.14 | 18,938,795.04 | -6,467,871.93 | -5,899,298.78 |
| 资产减值损失(新) | - | 0 | 708,089.19 | 708,089.19 |
| 信用减值损失(新) | 27,180,110.18 | -69,614,649.77 | -42,741,474.43 | -19,570,124.7 |
| 其他收益 | 215,831.84 | 2,368,696.35 | 1,869,258.5 | 1,371,992.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 23,679,569.85 | 25,532,765.3 | 53,336,454.16 | 43,089,470.95 |
| 加:营业外收入 | 434,213.66 | 20,336,749.52 | 1,850,298.04 | 982,757.83 |
| 减:营业外支出 | 721,816.93 | 4,300,677.24 | 8,072,922.87 | 3,886,179.09 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 23,391,966.58 | 41,568,837.58 | 47,113,829.33 | 40,186,049.69 |
| 减:所得税费用 | 3,956,590.71 | 551,027.32 | -5,135,191.98 | -365,935.21 |
| 六、净利润 | 19,435,375.87 | 41,017,810.26 | 52,249,021.31 | 40,551,984.9 |
| 持续经营净利润 | 19,435,375.87 | 41,017,810.26 | 52,249,021.31 | 40,551,984.9 |
| 归属于母公司股东的净利润 | 14,171,093.11 | 20,621,581.94 | 38,806,313.59 | 31,025,324.74 |
| 少数股东损益 | 5,264,282.76 | 20,396,228.32 | 13,442,707.72 | 9,526,660.16 |
| (一)基本每股收益 | 0.01 | 0.01 | 0.03 | 0.02 |
| (二)稀释每股收益 | 0.01 | 0.01 | 0.03 | 0.02 |
| 九、综合收益总额 | 19,435,375.87 | 41,017,810.26 | 52,249,021.31 | 40,551,984.9 |
| 归属于母公司股东的综合收益总额 | 14,171,093.11 | 20,621,581.94 | 38,806,313.59 | 31,025,324.74 |
| 归属于少数股东的综合收益总额 | 5,264,282.76 | 20,396,228.32 | 13,442,707.72 | 9,526,660.16 |
| 公告日期 | 2025-04-30 | 2025-04-24 | 2024-10-31 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |